Literature DB >> 15382066

Significant proportion of breast and/or ovarian cancer families of French Canadian descent harbor 1 of 5 BRCA1 and BRCA2 mutations.

Kathleen K Oros1, Parviz Ghadirian, Celia M T Greenwood, Chantal Perret, Zhen Shen, Yosabeth Paredes, Suzanna L Arcand, Anne-Marie Mes-Masson, Steven A Narod, William D Foulkes, Diane Provencher, Patricia N Tonin.   

Abstract

In 1998, we reported that a significant proportion of breast and/or ovarian cancer families of French Canadian descent harbor specific germline mutations in BRCA1 or BRCA2 attributed to common founders. Here we report the frequency of previously described mutations (n = 7) and 13 mutations identified in French Canadian families since 1998, in a new group of families (n = 88). Four of the previously described mutations, 4446C>T, 2953delGTAinsC, 8765delAG and 6085C>T, account for 72% and 69% of mutation-positive families in previously (n = 81) and recently ascertained groups, respectively. Only 2 of 13 recently identified mutations were found in more than 1 family: 3875delGTCT (n = 2) and 3398delAAAAG (n = 4). The 2 groups (ascertained pre- and post-gene discovery) did not differ significantly when distribution of mutations based on cancer syndrome phenotype and age of diagnosis or number of breast cancer cases were compared. Five common mutations accounted for a significant proportion (84%) of all mutation-positive families. The age of diagnosis of female breast cancer in mutation-negative families was significantly higher than that of the mutation-positive families (p<0.0001). The total number of cases of cancer per family was significantly lower in mutation-negative than mutation-positive families (p<0.001). Our results define a new mutation panel for screening BRCA1/2 mutations and the phenotype of mutation-positive families harboring the common mutations in the French Canadian population.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15382066     DOI: 10.1002/ijc.20406

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  22 in total

1.  Identification of the prevalent BRCA1 and BRCA2 mutations in the female population of Puerto Rico.

Authors:  Julie Dutil; Jose L Colon-Colon; Jaime L Matta; Rebecca Sutphen; Miguel Echenique
Journal:  Cancer Genet       Date:  2012-05

2.  Double PALB2 and BRCA1/BRCA2 mutation carriers are rare in breast cancer and breast-ovarian cancer syndrome families from the French Canadian founder population.

Authors:  Frédéric Ancot; Suzanna L Arcand; Anne-Marie Mes-Masson; Diane M Provencher; Patricia N Tonin
Journal:  Oncol Lett       Date:  2015-04-20       Impact factor: 2.967

3.  Evaluation of BRCA1 and BRCA2 mutation prevalence, risk prediction models and a multistep testing approach in French-Canadian families with high risk of breast and ovarian cancer.

Authors:  Jacques Simard; Martine Dumont; Anne-Marie Moisan; Valérie Gaborieau; Hélène Malouin; Francine Durocher; Jocelyne Chiquette; Marie Plante; Denise Avard; Paul Bessette; Claire Brousseau; Michel Dorval; Béatrice Godard; Louis Houde; Yann Joly; Marie-Andrée Lajoie; Gilles Leblanc; Jean Lépine; Bernard Lespérance; Hélène Vézina; Jillian Parboosingh; Roxane Pichette; Louise Provencher; Josée Rhéaume; Daniel Sinnett; Carolle Samson; Jean-Claude Simard; Martine Tranchant; Patricia Voyer; Douglas Easton; Sean V Tavtigian; Bartha-Maria Knoppers; Rachel Laframboise; Peter Bridge; David Goldgar
Journal:  J Med Genet       Date:  2006-08-11       Impact factor: 6.318

4.  Comprehensive BRCA1 and BRCA2 mutation analyses and review of French Canadian families with at least three cases of breast cancer.

Authors:  Luca Cavallone; Suzanna L Arcand; Christine M Maugard; Serge Nolet; Louis A Gaboury; Anne-Marie Mes-Masson; Parviz Ghadirian; Diane Provencher; Patricia N Tonin
Journal:  Fam Cancer       Date:  2010-12       Impact factor: 2.375

5.  A review of histopathological subtypes of ovarian cancer in BRCA-related French Canadian cancer families.

Authors:  Patricia N Tonin; Christine M Maugard; Chantal Perret; Anne-Marie Mes-Masson; Diane M Provencher
Journal:  Fam Cancer       Date:  2007-07-17       Impact factor: 2.375

6.  Derivation and characterization of matched cell lines from primary and recurrent serous ovarian cancer.

Authors:  Isabelle J Létourneau; Michael C J Quinn; Lu-Lin Wang; Lise Portelance; Katia Y Caceres; Louis Cyr; Nathalie Delvoye; Liliane Meunier; Manon de Ladurantaye; Zhen Shen; Suzanna L Arcand; Patricia N Tonin; Diane M Provencher; Anne-Marie Mes-Masson
Journal:  BMC Cancer       Date:  2012-08-29       Impact factor: 4.430

7.  Haplotype analysis suggest common founders in carriers of the recurrent BRCA2 mutation, 3398delAAAAG, in French Canadian hereditary breast and/ovarian cancer families.

Authors:  Kathleen K Oros; Guy Leblanc; Suzanna L Arcand; Zhen Shen; Chantal Perret; Anne-Marie Mes-Masson; William D Foulkes; Parviz Ghadirian; Diane Provencher; Patricia N Tonin
Journal:  BMC Med Genet       Date:  2006-03-15       Impact factor: 2.103

8.  BRCA1 and BRCA2 mutation predictions using the BOADICEA and BRCAPRO models and penetrance estimation in high-risk French-Canadian families.

Authors:  Antonis C Antoniou; Francine Durocher; Paula Smith; Jacques Simard; Douglas F Easton
Journal:  Breast Cancer Res       Date:  2005-12-12       Impact factor: 6.466

9.  Analysis of PALB2/FANCN-associated breast cancer families.

Authors:  Marc Tischkowitz; Bing Xia; Nelly Sabbaghian; Jorge S Reis-Filho; Nancy Hamel; Guilan Li; Erik H van Beers; Lili Li; Tayma Khalil; Louise A Quenneville; Atilla Omeroglu; Aletta Poll; Pierre Lepage; Nora Wong; Petra M Nederlof; Alan Ashworth; Patricia N Tonin; Steven A Narod; David M Livingston; William D Foulkes
Journal:  Proc Natl Acad Sci U S A       Date:  2007-04-09       Impact factor: 11.205

10.  Contribution of the PALB2 c.2323C>T [p.Q775X] founder mutation in well-defined breast and/or ovarian cancer families and unselected ovarian cancer cases of French Canadian descent.

Authors:  Marc Tischkowitz; Nelly Sabbaghian; Nancy Hamel; Carly Pouchet; William D Foulkes; Anne-Marie Mes-Masson; Diane M Provencher; Patricia N Tonin
Journal:  BMC Med Genet       Date:  2013-01-09       Impact factor: 2.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.